Daniel Shelly
Chief Business Development Officer PolTREG
Dan Shelly is a member of the Executive Leadership Team at PolTREG/Immuthera, responsible for advancing next-generation T-regulatory cell therapies for autoimmune disease. Former VP of Business Development & Alliances at Prescient Therapeutics, supporting CAR-immune cell platforms and targeted therapies. Previously Director of Global Business Development at PATH and Co-Lead of its COVID-19 task force. Brings 19+ years of biopharma BD, licensing & alliance experience. Adjunct professor in the Masters in Clinical Drug Development program at University of Cincinnati College of Pharmacy.
